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A B S T R A C T
In-vitro metronidazole resistance rates of Helicobacter pylori determined by Etest are high, and the
predictive value of metronidazole resistance is low. It was hypothesised that altered laboratory
methods could reduce the overestimation of resistance and improve the predictive value of the Etest.
Pre-treatment isolates (n ¼ 150) of H. pylori from 150 patients were investigated by Etest with
incubation for 72 h. Treatment with metronidazole, tetracycline and bismuth for 10 days failed to
eradicate H. pylori in 23 patients. After isolate storage for 3 years, resistance determination results by
agar dilution and Etest, with incubation for 72 and 31 h, were compared. The rate of metronidazole
resistance was reduced significantly during storage, and instability of resistance was associated
significantly with treatment outcome. Isolates that retained in-vitro resistance had significantly
(p 0.008) higher treatment failure rates (n ¼ 13; 42%) than isolates that lost resistance (n ¼ 3; 9%). The
reproducibility achieved by dual testing with agar dilution and Etest was 41% and 70% for ± 1 and
± 2 log2 dilutions, respectively, after incubation for 72 h, and 85% and 92%, respectively, after
incubation for 31 h. Thus, the predictive value was improved from 25% to 50% by the altered
laboratory conditions (p 0.04). MIC values of 2–8 mg ⁄L signified an intermediate risk of treatment
failure.
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I N T R O D U C T I O N
Although the prevalence of in-vitro metronidaz-
ole resistance in Helicobacter pylori varies world-
wide, it is generally found to be very high [1–10].
The association between in-vitro metronidazole
resistance and failure to eradicate H. pylori
following triple-drug therapy is weak [1–9,11].
Eradication therapy is therefore commonly pre-
scribed, and large treatment studies are conduc-
ted without determination of metronidazole
resistance [10–15].
The extent to which particular laboratory pro-
cedures might affect the outcome of resistance
determination with the Etest has not been eluci-
dated. Although reproducibility of in-vitro resist-
ance tests is good when the same procedure is
repeated with a single suspension [16–21], the
influence of variations in laboratory handling,
including the impact of storage on the test’s
predictive value, is not known. Therefore, in-vitro
metronidazole resistance was examined by
performing Etests on pre-treatment isolates pre-
and post-storage, and relating the results to the
outcome of triple-drug therapy. Furthermore, the
impact of using different periods of incubation
(72 h vs. 31 h) was assessed. The possible exist-
ence of a concentration zone of intermediate
resistance was also investigated. The standard
reference method, agar dilution, was used for
comparison.
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M A T E R I A L S A N D M E T H O D S
Between September 1995 and March 1996, 248 patients were
included in a Norwegian multicentre study and treated for
H. pylori-related disorders with a 10-day course of bismuth
subnitrate 150 mg three-times-daily, oxytetracycline 500 mg
three-times-daily, and metronidazole 400 mg three-times-
daily. None of the patients had received anti-H. pylori
treatment previously [22]. Before treatment, gastric specimens
were harvested and sent to the Department of Microbiology,
Østfold Central Hospital, Fredrikstad, Norway, where resist-
ance tests were performed and the isolates stored. For
comparison of test procedures, the resistance of the stored
specimens was determined later, as described below, in three
laboratories using different methods.
H. pylori eradication failed in 34 patients. Pre-treatment
isolates from 23 of these patients were recoverable after
storage. Metronidazole resistance tests were also performed
with all three methods on 131 of 138 consecutive isolates from
214 patients treated successfully. Four of these were excluded
because of lack of crucial data. Thus, test results from 150
(127 + 23) isolates were analysed. The strains originated from
72 males and 78 females, with a median age of 61.5 years
(range 20–83 years).
Procedures for culture and resistance determination
Gastric specimens were ground and diluted in normal saline at
Østfold Central Hospital. Suspensions were cultured on
Columbia blood agar (Oxoid, Basingstoke, UK). H. pylori
colonies, defined by appearance and by positive catalase,
urease and oxidase reactions, were tested for in-vitro metroni-
dazole resistance as described below, and stored at ) 70 C
[22]. If initial growth was insufficient, isolates were subcul-
tured once on Columbia blood agar.
After storage for 3 years, isolates were cultured on three
Columbia blood agar plates. After 3 days, two plates of the
recovered isolates were sent, in micro-aerobic jars at 37 C, to
separate laboratories within a 5-h travelling radius.
The pre-storage Etest (AB Biodisk, Solna, Sweden) for
in-vitro metronidazole resistance determination was per-
formed at Østfold Central Hospital with chocolate agar plus
Vitox (Oxoid). A heavy inoculum of c. 4 MacFarland standards
was used, and CampyGen (Oxoid) was used to produce a
micro-aerobic atmosphere. Plates were incubated for 72 h [22].
In-vitro metronidazole resistance was determined for post-
storage isolates by three methods. First, a post-storage Etest
was performed, as described above, by the same investigator
who conducted the pre-storage test. Second, an Etest with a
shorter incubation period was performed at the Department of
Microbiology, Sentralsykehuset i Vestfold, Tønsberg, Norway,
using Vestfold Charcoal Medium. This medium was based on
charcoal agar (Oxoid) and contained serum 10% v ⁄v and
IsoVitaleX 1% v ⁄v (Becton Dickinson, Franklin Lakes, NJ, USA)
[16,23,24]. BR 38 (Oxoid), without catalyst, was used to produce
a micro-aerobic atmosphere [25]. Plates were flooded with
2 mL of a 0.5 MacFarland standard. All extra fluid was
removed immediately, and the plates were allowed to dry
before Etest strips were applied. Plates were incubated for 31 h
[17]. Third, an agar dilution test was performed on Wilkinson–
Chalgreen agar (Oxoid) at Telelab, Skien, Norway [26]. After
subcultivation on chocolate agar (with BR 38, but without
catalyst), isolates were diluted in LB broth (Oxoid) to a density
of 3 MacFarland standards. Inoculation was performed with
the Scan 400 multipoint inoculator (Mast Laboratories, Bootle,
UK), which transferred 0.3 lL ⁄ spot. Plates were incubated at
37 C for 72 h in a micro-aerobic atmosphere and read
manually.
When colonies were found within the inhibition zone by
any of the methods, the isolate was recorded as being highly
metronidazole-resistant (MIC > 32 mg ⁄L).
Statistics
Median MIC values before and after storage were com-
pared by use of the Mann–Whitney U-test. The occurrence of
treatment failures among isolates that lost or retained their
pre-treatment metronidazole resistance (MIC > 8 mg ⁄L) dur-
ing storage was compared using the chi-square test with
Yates’ correction. The statistical significance of the change in
resistance identified with the Etest with 72 h of incubation
was evaluated with McNemar’s test for paired observations
[27]. The rate of treatment failure among isolates with
high MIC values (> 8 mg ⁄L), i.e., the positive predictive
value, was calculated for each of the procedures. The
significance of the change in predictive value of the Etest
was evaluated with the chi-square test for trends [27], using
the following ordering: pre-storage Etest with 72 h of incu-
bation, post-storage Etest with 72 h of incubation, and,
finally, post-storage Etest with a shorter incubation time.
Based on studies of recipient operating characteristic (ROC)
curves, the existence of an MIC range of intermediate
sensitivity was identified.
R E S U L T S
The median MIC value was reduced significantly
during storage from 5.8 mg ⁄L to 0.8 mg ⁄L
(p 0.001). Unstable resistance, i.e., a change in
resistance status during storage, was found in
40 (27%) isolates. Thirty isolates lost in-vitro
resistance (defined as an MIC > 8 mg ⁄L) during
storage, while ten isolates gained resistance
(p 0.002). The ability of isolates to retain resist-
ance throughout storage was associated signifi-
cantly with treatment outcome. Treatment failure
was thus significantly more prevalent among
isolates with retained resistance than among
isolates that lost their resistance (v2 ¼ 7.2;
p 0.008) (Table 1).
There was a major difference between the two
Etest methods with respect to their ability to
reproduce results obtained with the agar dilution
method (Table 2). The proportion of reproducible
results, within both ± 1 and ± 2 double dilution
gradients, was significantly higher with the shor-
ter-incubation Etest method than with the stand-
ard Etest (p < 0.0005).
Treatment failure, i.e., the positive predictive
value of the test, was numerically higher among
patients with isolates that were resistant after
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storage compared to before, but this was not
significant (35% and 25%, respectively; p 0.43).
However, the predictive value was improved
significantly with the shorter-incubation Etest
(p 0.04) (Fig. 1). Hence, the best prediction of
treatment failure (50%) was achieved with the
shorter-incubation Etest on post-storage isolates.
In-vitro resistance was defined throughout the
study as an MIC > 8 mg ⁄L. According to the ROC
curves, the post-storage Etest, the shorter-incuba-
tion Etest and the agar dilution method had
additional breakpoints at 3, 2 and 2 mg ⁄L,
respectively (Fig. 2). MIC values in the interval
between these breakpoints and 8 mg ⁄L were
associated with treatment failure rates that were
intermediate between failure rates at high and
low MIC values (Table 3). For the agar dilution
method and the modified Etest, treatment
failure rates were significantly lower for isolates
with MICs £ 2 mg ⁄L when compared to those
with intermediate sensitivity (MIC>2–8 mg ⁄L)
(p 0.005 and 0.007, respectively).
D I S C U S S I O N
In-vitro metronidazole resistance was found to be
unstable, as the sensitivity status altered in 27%
of isolates during storage at ) 70 C. Further-
more, this loss of resistance was selective, as 29
(62%) isolates that were eradicated lost in-vitro
resistance, compared to three (19%) treatment-
resistant isolates (p 0.008). Stability of in-vitro
resistance during storage was thus an important
indicator of potential failure with triple-drug
therapy.
It is known that the Etest may overestimate
metronidazole resistance [16,28]. However,
reduced overestimation following storage has
not been reported previously, and could be
associated with loss of resistance heterogeneity.
In this context, resistance heterogeneity occurs
when individual bacteria express MIC values that
differ from those of the main proportion of the
population [29,30]. Such resistance heterogeneity
has been found in 33% of isolates [29], and
individual bacteria with a four-fold increase in the
metronidazole MIC were reported to occur at a
rate of up to 5 · 10)5 in one study [31]. As the
number of colonies that can be recovered from the
frozen state and cultured on agar plates is
normally < 1 · 103 [25], the number of colonies
obtained on agar plates may be too small to
regularly transmit heterogeneous resistance.
Hence, even at a high rate of occurrence, there is
Table 2. Comparison of Etest results after incubation for 31 and 72 h, respectively, with agar dilution results for
metronidazole resistance determination with 150 Helicobacter pylori isolates
Duration
of incubation
No. of Etest determinations within indicated number of log2 dilutions Agreement (%)
> ) 4 ) 4 ) 3 ) 2 ) 1 0 1 2 3 4 > 4
± 1 log2
dilution
± log2
dilution
31 h 2 6 8 34 71 23 2 1 1 2 85.3% 92%
72 h 1 7 19 31 25 30 13 6 3 5 10 41.3% 70%
Fig. 1. Predictive value for eradication failure with four
different test procedures.
Table 1. Impact of storage: the association between con-
served vs. lost in-vitro metronidazole resistance
(MIC > 8 mg ⁄L) and the outcome of eradication therapy
Resistance
conserved
Resistance
lost
Outcome of therapy
Failure 13 3
Success 18 29
p 0.008; n ¼ 63.
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a substantial potential for loss of such heterogen-
eity during storage.
Resistance heterogeneity predicts failure of
monotherapy [19,31–33]. However, there is no
evidence for an association between the occur-
rence of a few colonies within the metronidazole
inhibition zone and failure of triple-drug therapy,
although this has been assumed in a number of
studies [4,18,22,34]. It is of note that, although a
proper lawn of strong bacterial growth around a
distinct inhibition zone is seen after incubation for
31 h under optimal conditions, single colonies
within the inhibition zone are not observed at this
point. Therefore, heterogeneity, expressed as
single colonies growing within the inhibition
zone, was not observed with the best-performing
method in this study, i.e., the shorter-incubation
Etest.
A diversity of agars has been used for resist-
ance testing, in spite of the fear that different
chemicals and nutrients may affect the test result
[1,4,5,26]. Charcoal media are generally avoided
for this reason, but determination of metronidaz-
ole resistance is exceptional, as the results of dual
metronidazole resistance testing on charcoal and
chocolate agars are in full agreement [16]. The
only medium tested for resistance determination
of H. pylori after incubation for 31 h contains
charcoal [17]. Wilkinson–Chalgreen’s agar has
been recommended and is commonly used for
resistance testing in the agar dilution method, as
in the present study, although the potential of this
medium to cause altered metronidazole MIC
values has been raised [26].
Several factors may contribute to the problems
involved in determination of resistance in
H. pylori, including chemicals and nutrients found
in the different culture atmospheres and media
used [4,16,25], and their impact will depend
entirely upon the duration of incubation. Inter-
estingly, in this and other studies [4,16], improved
reproducibility was associated with a short period
of incubation. For most bacterial species, correct
and short incubation periods are important for the
standardisation of resistance testing procedures
[32,33,35–37]. Little has been done to assess
the negative effect of prolonged incubation
(commonly 72 h) of H. pylori, as this is a fastidious
species, and it is believed that a shorter incubation
time is both impractical and not required
[19–21,31–33]. However, the reproducibility of
readings is not optimal, even containing major
Fig. 2. ROC curves for the studied test procedures. Posi-
tion of 8 mg ⁄L and the alternative breakpoints are indica-
ted.
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errors, when incubation for 48–72 h is used with
the disk diffusion method [18,21,28]. The repro-
ducibility of results obtained with this method is
improved significantly by limiting the incubation
time to 31 h [17].
In the present study, the agar dilution method
appeared to perform optimally with an incuba-
tion time of 72 h (Table 3), and this is in
accordance with previous observations [18,28].
It has been more difficult to define the optimal
time conditions for metronidazole resistance
determination with the Etest [4,16,18,28]. In one
study, it was found that incubation for 72 h gave
optimal reproducibility of test results when the
size and age of inocula were optimised and
standardised [38]. It was also observed previ-
ously that test reproducibility was significantly
improved when the incubation period was
reduced from 72 to 48 h [16]. In the present
study, there were a number of methodological
differences between the two Etest procedures, so
interpretations should be made with care, but
one possible explanation for the improved repro-
ducibility observed with a shorter incubation
time is that 72 h is too long a period of incuba-
tion for the Etest (Table 2).
Redox potential variations are known to alter
the outcome of in-vitro metronidazole resistance
tests. Anaerobic preincubation of culture plates,
and incubation at very low oxygen tension, are
known to reduce MICs of metronidazole [34]. In
the present study, the same method was used to
produce the culture atmosphere before and after
storage, and anaerobic preincubation was not
applied. Therefore, there is no reason to assume
that the observed shift in resistance during stor-
age could be attributed to changes in atmospheric
conditions.
For H. pylori, the gap between failure rates for
high and low MIC values has been so small that
intermediate resistance rates have not been an
issue. In the present study, the difference between
failure rates with high and low MIC values before
storage was only 17%. With improved proce-
dures for resistance determination, the difference
increased, which supports the assumption that
intermediate resistance also exists for H. pylori.
This is in accordance with a previous error rate
analysis on post-storage isolates, which found
that the occurrence of major errors was reduced
when an intermediate category was included in
the susceptibility classification scheme [38]. For
patients harbouring bacteria with MICs in this
area of critical sensitivity, the type of treatment
given in addition to metronidazole, as well as
therapy length and compliance, may be of partic-
ular importance.
In conclusion, metronidazole resistance, as
determined with the Etest, reduced significantly
during storage. Dual testing by Etest and agar
dilution yielded poor reproducibility, but this was
improved significantly by modification of the
Etest procedure. Alteration of the laboratory
conditions led to an improvement in the predic-
tive value of the Etest from 25% to 50%. In
addition, rather than appearing at one specified
breakpoint value, the risk of treatment failure was
found to grow gradually, thus forming a level of
intermediate resistance for MIC values within the
range 2–8 mg ⁄L.
Table 3. Comparison of three methods for metronidazole resistance determination by pre-treatment MIC values and
treatment outcomes
MIC
(mg/L)
Etest
Incubation for 72 h Incubation for 31 h Agar dilution
ER NE Failure rate ER NE Failure rate ER NE Failure rate
< 2 86 7 7 ⁄ 100 (7%) 59 3 4 ⁄ 86 (5%) 33 3 5 ⁄ 94 (5%)
2 3 0 23 1 56 2
3 4 0 20 5 10 ⁄ 46 (22%) 0 0 8 ⁄ 32 (25%)
4 2 1 2 ⁄ 9 (22%) 10 5 21 4
6 2 1 5 0 0 0
8 3 0 1 0 3 4
12 1 0 14 ⁄ 41 (34%) 0 1 9 ⁄ 18 (50%) 0 0 10 ⁄ 24 (42%)
16 1 1 0 0 3 2
‡ 32 25 13 9 8 11 8
ER, eradicated; NE, not eradicated.
Failure rates are given for low, intermediate and high MIC values. The higher breakpoint value was defined as 8 mg ⁄L according to common criteria; the lower breakpoint
value was defined by ROC curves (Fig. 2).
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